Alterity Therapeutics Stock | Forecast, Price Target & Outlook 2026

Alterity Therapeutic...

ASX:ATH

$ 0,01

$0,00 (0,00%)

0,01 $

$0,00 (0,00%)

End-of-day quote: 04/10/2026

Alterity Therapeutics Stock Value

Analysts currently give ASX:ATH a rating of Buy.

Buy

Alterity Therapeutics Company Info

EPS Growth 5Y

0,00%

Market Cap

$0,10 B

Long-Term Debt

$0,00 B

Quarterly earnings

N/A

Dividend

$0,00

Dividend Yield

0,00%

Founded

1997

Industry

Health Care

Country

Australia

Website

Alterity Therapeutics

ISIN Number

AU0000043945

Website

http://alteritytherapeutics.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,04

300%

Last Update: 04/11/2026

Analysts: 2

Highest Price Target $0,07

Average Price Target $0,04

Lowest Price Target $0,02

In the last five quarters, Alterity Therapeutics’s Price Target has risen from $0,03 to $0,04 - a 33,33% increase. One analysts predict that Alterity Therapeutics’s share price will increase in the coming year, reaching $0,04. This would represent an increase of 300,00%.

Top growth stocks in the health care sector (5Y.)

What does Alterity Therapeutics do?

Alterity Therapeutics Limited is an innovative biotechnology company focused on developing therapies to treat neurodegenerative diseases. Business Segments The company has organized its operations into key segments: Research and Development (R&D), Clinical Development, Regulatory Affairs, and Commercialization. Research and Development: The R&D segment drives innovation by focusing on discovering therapeutic candidates for neurodegenerative diseases, targeting unique neurobiological mechanism...

Alterity Therapeutics Limited is an innovative biotechnology company focused on developing therapies to treat neurodegenerative diseases.

Business Segments

The company has organized its operations into key segments: Research and Development (R&D), Clinical Development, Regulatory Affairs, and Commercialization.

Research and Development: The R&D segment drives innovation by focusing on discovering therapeutic candidates for neurodegenerative diseases, targeting unique neurobiological mechanisms.

Clinical Development: The Company Identified lead candidates move through preclinical testing and clinical trials, where the company rigorously evaluates their safety and efficacy while ensuring compliance with regulatory standards.

Regulatory Affairs: This segment navigates drug approval processes, ensuring that all trials and applications meet health authority requirements, facilitating smooth interactions with regulatory agencies.

Commercialization: This segment focuses on strategic partnerships and market access strategies to distribute successful therapies effectively, ensuring they reach the patients who need them most.

Business Strategy

The Company business strategy emphasizes innovation in biotechnology while ensuring financial sustainability.

The Company focuses on strategic investments in R&D and forming collaborations with academic institutions and industry partners to enhance research efficacy and accelerate therapy development. Transparency is key, as the company actively shares progress with stakeholders, including investors, healthcare providers, and the patient community, to build trust and engagement.

To support its operations, the company explores diverse funding sources such as venture capital, government grants, and partnerships with established pharmaceutical firms, ensuring it maintains research momentum without compromising quality or compliance.

Products and Services

The Company specializes in a range of products and services focused on neurodegenerative disease therapies. The primary products in development include.

Therapeutic Drug Candidates: These include several investigational drugs that target specific neurological mechanisms in diseases such as Alzheimer's and Parkinson's.

Preclinical and Clinical Services: The Company offers comprehensive services for preclinical and clinical stages, which include design, protocol development, patient recruitment, and data analysis.

Regulatory Support: The Company provides regulatory consultancy services aimed at navigating drug application processes, including strategic insights for clinical trial submissions and negotiations with regulatory authorities.

Geographical Markets Served

The Company primarily operates in the international arena, focusing on markets with significant demand for neurodegenerative disease therapeutics. Major geographical markets served include Australia, North America, Europe, and parts of Asia. The Company is committed to expanding its reach by exploring opportunities in emerging markets while maintaining a strong presence in established regions.

Customers

The Company primarily serves healthcare providers, research institutions, and pharmaceutical companies. The Company's customer base is characterized by its focus on organizations and entities engaged in neurological research and therapy development.

Sales and Marketing

The Company utilizes a multi-faceted approach. The Company emphasizes direct engagement with stakeholders, including healthcare professionals and potential collaborators. Trade conferences, publications, and online platforms are also leveraged to market its innovations and research breakthroughs.

Government Regulations

The Company adheres to regulations set by health authorities in various markets, including the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States.

History

Alterity Therapeutics Limited was incorporated in 1997. The Company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

New support ticket

Explore

Alterity Therapeutics Stock Value

Alterity Therapeutics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alterity Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Alterity Therapeutics Stock Value

Alterity Therapeutics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alterity Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.